PNC Financial Services Group
RNAC icon

PNC Financial Services Group’s Cartesian Therapeutics RNAC Stock Holding History

PNC Financial Services Group’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.29K Buy
124
+88
+244% +$652 ﹤0.01% 4794
2026
Q1 		$221 Buy
36
+31
+620% +$221 ﹤0.01% 5022
2025
Q4 		$36 Buy
+5
New +$40 ﹤0.01% 5113
2022
Q3 		– Sell
-2
Closed – – 4587
2022
Q2 		$0 Buy
+2
New +$59 ﹤0.01% 4679

Other funds holding RNAC

Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PNC Financial Services Group's RNAC Position: Q2 2026 in Review

PNC Financial Services Group increased its Cartesian Therapeutics (RNAC) stake by 244% in Q2 2026, buying an estimated $652 and bringing the position to 124 shares worth $1.29K. The position accounts for ﹤0.01% of the portfolio, ranked #4794.

PNC Financial Services Group first reported a position in RNAC in Q2 2022 and has held it in 4 quarters since. 95 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

  • PNC Financial Services Group held 124 shares of Cartesian Therapeutics worth $1.29K as of Q2 2026.
  • PNC Financial Services Group bought 88 Cartesian Therapeutics shares in Q2 2026, an estimated $652.
  • Cartesian Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #4794 holding.
  • PNC Financial Services Group first reported a position in Cartesian Therapeutics in Q2 2022 and has held it in 4 quarters since.
  • 95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.